Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females, age 55-85
Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) Diagnostic and Statistical Manual of Mental Disorders (DSM IV)
Mini-mental status exam score of 14-26 inclusive
Rosen-Modified Hachinski Ischemia Score of \< or = 4
You may not be if
Diagnosis or history of other dementia or neurodegenerative disorders
Diagnosis or history of clinically significant cerebrovascular or cardiovascular disease
Subjects with pulmonary disease or evidence of clinically significant pulmonary symptoms
